Exploration of the association between <i>SF3B4</i> and <i>HMGB1</i> expression and the clinicopathological features and prognosis of gastric cancer

Elevated <i>SF3B4</i> and <i>HMGB1</i> expression in gastric cancer tissue is significantly associated with tumor aggressiveness, worse prognosis, and reduced survival. These biomarkers may offer clinical value in stratifying patients by risk and in forecasting outcomes. Their combined assessment improves predictive accuracy for poor prognosis and may serve as a more effective tool than individual evaluation.